hypophosphatemia/tyrosine

Odkaz sa uloží do schránky

Vyberte typ zoradenia

Strana 1 od 32 výsledky

[Investigation and Measurement of Hypophosphatemia Induced by Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia].

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

We retrospectively investigated hypophosphatemia induced byty rosine kinase inhibitors(TKIs), in patients with chronic myeloid leukemia. Subjects evaluated were 14, 11, and 8 patients who received TKIs(imatinib, dasatinib and nilotinib), respectively, at the Department of Hematology in Ichinomiya

A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Ibrutinib, an irreversible oral inhibitor of Bruton's tyrosine kinase, has been used in the treatment of patients with multiple hematologic malignancies. A 59-year-old male with chronic lymphocytic leukemia was treated with 420 mg/day of ibrutinib. No evidence of bruising or diarrhea was noted. The

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND Nilotinib, a second-generation tyrosine kinase inhibitor (TKI) formerly known as AMN107, was approved by the US Food and Drug Administration (FDA) on October 29, 2007, for the treatment of adult patients with chronic-phase (CP) and accelerated-phase (AP) Philadelphia chromosome-positive

Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Tyrosine kinase inhibitors (TKIs) are at the forefront of molecular-targeted therapies for cancer. With the advent of imatinib for the treatment of chronic myelogenous leukemia, a new wave of small-molecule therapeutics redefined the oncologic treatment to become chronically administered medications

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Polyclonal emergence of KIT secondary mutations is a main mechanism of imatinib progression in gastrointestinal stromal tumor (GIST). Approved KIT inhibitors sunitinib and regorafenib have complementary activity against KIT resistance mutations. Preclinical evidence suggests that rapid

Real-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND Various tyrosine kinase signalling pathways affect the development and progression of colorectal cancer (crc). In clinical trials, regorafenib has been associated with a survival benefit in metastatic crc (mcrc). We assessed the safety and efficacy of regorafenib in real-world

[Mutation analysis of FAH gene in patients with tyrosinemia type 1].

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To investigate the clinical features and mutations of the FAH gene. METHODS Clinical records of two cases were collected, and diagnosis was made according to the diagnostic criteria of the International Organization for Rare Disorders (NORD). Genomic DNA was extracted from peripheral blood

Dysregulation of bone remodeling by imatinib mesylate.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Imatinib mesylate is a rationally designed tyrosine kinase inhibitor that has revolutionized the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Although the efficacy and tolerability of imatinib are a vast improvement over conventional chemotherapies, the drug exhibits

Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their inhibitory target profile and efficacy as single agents, the combination of these drugs is of considerable interest in solid

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma. METHODS This multi-institutional non-randomized phase II trial enrolled two cohorts: patients with uterine

Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To review the common and serious toxicities associated with the use of tyrosine kinase inhibitors such as sorafenib and sunitinib and mTOR inhibitor temsirolimus, and to outline the most recent toxicity management guidelines. RESULTS Common grade 3 or 4 side effects with sorafenib include

Supplements containing amino acids and keto acids in the treatment of chronic uremia.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Three mixtures containing varying proportions of threonine, tyrosine, and the ornithine, lysine, and histidine salts of branched-chain keto acids have been tested as dietary supplements to a 20- to 25-g mixed-quality protein diet in patients with severe chronic uremia. Two of the three supplements

Expanding the phenotype of hawkinsinuria: new insights from response to N-acetyl-L-cysteine.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Hawkinsinuria is a rare disorder of tyrosine metabolism that can manifest with metabolic acidosis and growth arrest around the time of weaning off breast milk, typically followed by spontaneous resolution of symptoms around 1 year of age. The urinary metabolites hawkinsin, quinolacetic acid, and

Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Neuroendocrine tumors (NETs) can secrete hormones, including ectopic secretions, but they have been rarely associated with malignant hypercalcemia. A 52-year-old man with a history of diabetes mellitus was diagnosed with a pancreatic tumor. A pancreatic biopsy confirmed a well-differentiated

Long-term imatinib therapy promotes bone formation in CML patients.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Imatinib inhibits tyrosine kinases important in osteoclast (c-Fms) and osteoblast (platelet-derived growth factor receptor [PDGF-R], c-Abl) function, suggesting that long-term therapy may alter bone homeostasis. To investigate this question, we measured the trabecular bone volume (TBV) in iliac

Predchádzajúce
1
2
3
Ďalšie

Pripojte sa k našej
facebookovej stránke

Herbal & Natural Medicine

Najkompletnejšia databáza liečivých bylín podporovaná vedou

Pracuje v 55 jazykoch
Bylinné lieky podporené vedou
Rozpoznávanie bylín podľa obrázka
Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
Vyhľadajte liečivé byliny podľa ich účinkov
Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume